ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+55.54%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$7.04B
AUM Growth
+$7.04B
(+39%)
Cap. Flow
+$374M
Cap. Flow
% of AUM
5.32%
Top 10 Holdings %
Top 10 Hldgs %
74.64%
Holding
53
New
9
Increased
20
Reduced
11
Closed
7
Top Buys
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$161M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$128M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$64.1M |
| 4 |
PMV Pharmaceuticals
PMVP
|
$57.6M |
| 5 |
Kura Oncology
KURA
|
$42.4M |
Top Sells
| 1 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
$115M |
| 2 |
Allogene Therapeutics
ALLO
|
$48.3M |
| 3 |
Iovance Biotherapeutics
IOVA
|
$27.2M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
$27.1M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
$24.7M |
Sector Composition
| 1 | Healthcare | 66.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| $2.23B | 31.71% | 26,250,000 | – | – |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $721M | 10.25% | 4,343,000 +56,235 | +1% | +$9.34M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $594M | 8.44% | 7,650,000 +1,650,000 | +28% | +$128M |
|
|
4
Iovance Biotherapeutics
IOVA
$807M
| $314M | 4.46% | 9,536,039 -825,000 | -8% | -$27.2M |
|
5
Ascendis Pharma
ASND
$11.8B
| $278M | 3.95% | 1,800,000 +50,000 | +3% | +$7.72M |
|
|
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $257M | 3.65% | 1,885,000 +5,000 | +0.3% | +$682K |
|
7
argenx
ARGX
$43.6B
| $237M | 3.37% | 902,500 -67,500 | -7% | -$17.7M |
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $235M | 3.34% | 1,675,000 | – | – |
|
|
ARNA
9
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $232M | 3.29% | 3,100,000 +2,150,000 | +226% | +$161M |
|
10
Amicus Therapeutics
FOLD
$2.34B
| $153M | 2.18% | 10,850,000 -150,000 | -1% | -$2.12M |
|
|
XLRN
11
DELISTED
Acceleron Pharma Inc.
XLRN
| $152M | 2.16% | 1,350,000 +310,000 | +30% | +$34.9M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $133M | 1.89% | 1,750,000 -100,000 | -5% | -$7.61M |
|
13
Mersana Therapeutics
MRSN
$36.5M
| $127M | 1.8% | 6,800,000 +300,000 | +5% | +$5.59M |
|
|
14
Madrigal Pharmaceuticals
MDGL
$9.76B
| $106M | 1.5% | 890,000 +540,000 | +154% | +$64.1M |
|
|
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $93.4M | 1.33% | 1,820,000 -40,000 | -2% | -$2.05M |
|
|
ADAP
16
Adaptimmune Therapeutics
ADAP
$15.6M
| $87.8M | 1.25% | 11,000,000 +1,000,000 | +10% | +$7.98M |
|
17
Karyopharm Therapeutics
KPTI
$61.7M
| $87.6M | 1.24% | 6,000,000 -1,000,000 | -14% | -$14.6M |
|
|
CNST
18
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $86.6M | 1.23% | 4,275,000 +275,000 | +7% | +$5.57M |
|
19
Adverum Biotechnologies
ADVM
$64.6M
| $82.4M | 1.17% | 8,000,000 +415,000 | +5% | +$4.27M |
|
|
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
| $78.2M | 1.11% | 5,500,000 +750,000 | +16% | +$10.7M |
|
|
21
Kura Oncology
KURA
$686M
| $74.6M | 1.06% | 2,435,000 +1,385,000 | +132% | +$42.4M |
|
|
CBAY
22
DELISTED
Cymabay Therapeutics
CBAY
| $74.6M | 1.06% | 10,300,000 +5,050,000 | +96% | +$36.6M |
|
23
uniQure
QURE
$896M
| $64.5M | 0.92% | 1,750,000 +250,000 | +17% | +$9.21M |
|
|
24
PMV Pharmaceuticals
PMVP
$74.2M
| $57.6M | 0.82% | +1,850,000 | New | +$57.6M |
|
25
Relmada Therapeutics
RLMD
$37.2M
| $56.4M | 0.8% | 1,500,000 +75,000 | +5% | +$2.82M |
|